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Rational combination treatment with histone deacetylase
inhibitors and immunomodulatory drugs in multiple myeloma
T Hideshima, F Cottini, H Ohguchi, J Jakubikova, G Gorgun, N Mimura, Y-T Tai, NC Munshi, PG Richardson and KC Anderson
Immunomodulatory drugs (IMiDs) thalidomide, lenalidomide (Len) and pomalidomide trigger anti-tumor activities in multiple
myeloma (MM) by targetting cereblon and thereby impacting IZF1/3, c-Myc and IRF4. Histone deacetylase inhibitors (HDACi) also
downregulate c-Myc. We therefore determined whether IMiDs with HDACi trigger signiﬁcant MM cell growth inhibition by
inhibiting or downregulating c-Myc. Combination treatment of Len with non-selective HDACi suberoylanilide hydroxamic acid or
class-I HDAC-selective inhibitor MS275 induces synergic cytotoxicity, associated with downregulation of c-Myc. Unexpectedly, we
observed that decreased levels of cereblon (CRBN), a primary target protein of IMiDs, was triggered by these agents. Indeed,
sequential treatment of MM cells with MS275 followed by Len shows less efﬁcacy than simultaneous treatment with this
combination. Importantly ACY1215, an HDAC6 inhibitor with minimal effects on class-I HDACs, together with Len induces
synergistic MM cytotoxicity without alteration of CRBN expression. Our results showed that only modest class-I HDAC inhibition is
able to induce synergistic MM cytotoxicity in combination with Len. These studies may provide the framework for utilizing HDACi in
combination with Len to both avoid CRBN downregulation and enhance anti-MM activities.
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INTRODUCTION
Despite progress due to development of proteasome inhibitors
(bortezomib, carﬁlzomib) and immunomodulatory drugs (IMiDs;
thalidomide, lenalidomide, pomalidomide), novel combination
treatment strategies are needed to further improve multiple
myeloma (MM) patient outcome. Recent studies have shown
cereblon to be a primary target of IMiDs:1–3 IMiDs bind to
cereblon, an E3 ubiquitin ligase which facilitates ubiquitination of
IKZF1 (Ikaros) and IKZF3 (Aiolos) followed by proteasomal
degradation. Indeed, IMiDs downregulate IKZF1/3 within several
hours, which is abrogated by proteasome inhibitors. Of note,
knockdown of IKZF1/3 induces signiﬁcant growth inhibition of
MM cells.4,5 Although human MM has multiple translocations
involving IgH switch regions, c-MYC is infrequently involved as a
partner in these translocations.6 However, it is commonly
activated in MM, and knockdown of MYC induces MM cell
death,7 suggesting that c-Myc represents a promising therapeutic
target in MM. Importantly, it has also shown that IMiDs
downregulate not only c-Myc, but also IRF4,3,8 which has a central
role in MM pathogenesis.6 These studies show that IMiDs inhibit
multiple key molecules that mediate MM cell proliferation, survival
and drug resistance in the context of the bone marrow (BM)
microenvironment.
Histones are localized in the nucleus and, as the predominant
protein components of chromatin, have a major role in modulat-
ing the binding of transcription factors to DNA. The activity of
histones is regulated by their acetylation status, which is tightly
mediated by both acetyltransferases and deacetylases. Histone
deacetylases (HDACs) are divided into distinct classes: class-I
(HDAC1, 2, 3 and 8), class-IIa (HDAC4, 5, 7 and 9), class-IIb (HDAC6
and 10), class-III (sirtuins) and class-IV (HDAC 11). HDACi are
hydroxamic acids, benzamides, cyclic peptides, ketones or
aliphatic acids, and each HDACi targets different isoforms of
HDAC.9 Recent studies have shown that HDACi are promising
anti-tumor agents in various malignancies and other diseases.10 In
MM, we have shown that non-selective HDACi induce anti-MM
activities in preclinical settings;11–13 however, their clinical
activities are limited due to unfavorable toxicities including
fatigue, diarrhea and thrombocytopenia attendant to broad
inhibition of HDAC isoforms.14
To exploit anti-MM activities while minimizing toxicities of
HDACi, class or isoform selective HDACi have recently been
developed. For example, we have shown that HDAC6 selective
inhibitors (tubacin, ACY1215) induce signiﬁcant anti-MM activities
in combination with proteasome inhibitors by blocking both
proteasomal and aggresomal protein degradation,15–17 and early
clinical trials demonstrate a favorable side effect proﬁle.18 Most
recently, we have developed HDAC3 selective small molecule
inhibitor BG45, which also shows signiﬁcant MM cell growth
inhibition in an in vivo murine xenograft MM model.19 Since
previous studies have shown that class-I/II HDAC inhibitors
downregulate c-Myc expression,20,21 we here examined whether
various HDACi together with IMiDs trigger both downregulation of
c-Myc and synergistic anti-MM activity, to provide the framework
for combination clinical trials.
MATERIALS AND METHODS
Cell lines, patient MM cells and BM stromal cell
MM.1S and NCI-H929 cells were obtained from American Type Culture
Collection (Manassas, VA, USA). All MM cell lines were cultured in
RPMI-1640 (Gibco, Grand Island, NY, USA) containing 10% fetal bovine
serum (Sigma Chemical Co., St. Louis, MO, USA), 2 μM L-glutamine, 100 U/ml
penicillin and 100 μg/ml streptomycin (Gibco). Patient MM cells were
puriﬁed as previously reported.17 To generate BM stromal cells (BMSCs),
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mononuclear cells separated by Ficoll-Hypaque density sedimentation
from BM aspirates were cultured in RPMI-1640 containing 15% fetal bovine
serum for 5–6 weeks. All experiments using patient samples were
performed according to a protocol approved by the Institutional Review
Board of Dana-Farber Cancer Institute.
Reagents and antibodies
Suberoylanilide hydroxamic acid (SAHA, vorinostat), LBH589 (panobino-
stat), MS275 (entinostat), lenalidomide (Len), pomalidomide (Pom) and
bortezomib (BTZ) were purchased from Selleck Chemicals (Houston, TX,
USA). HDAC6 inhibitor ACY1215 (ricolinostat) was obtained from Chemie-
Tek (Indianapolis, IN, USA). Anti-acetylated α-tubulin antibody (Ab) and
-cereblon Abs were purchased from Sigma (St. Louis, MO, USA). Anti-c-Myc,
anti-acetylated lysine, anti-glyceraldehyde 3-phosphate dehydrogenase
(GAPDH), anti-caspase-8, anti-caspase-9, anti-cleaved-caspase-3, anti-poly
(ADP-ribose) polymerase (PARP), anti-X-linked inhibitor of apoptosis
protein (XIAP), Bcl2, anti-cIAP2, anti-α-tubulin, phospho-STAT3, HDAC6,
IKZF1, IKZF3 and IRF4 Abs were obtained from Cell Signaling Technology
(Danvers, MA, USA). Anti-IKZF1 Abs were purchased from Cell Signaling
Technology or R&D Systems (Minneapolis, MN, USA) Figure 4d. Human
interleukin-6, insulin-like growth factor 1, vascular endothelial growth
factor and tumor necrosis factor α were obtained from R&D Systems.
Cell growth assay
Cell growth was assessed by measuring 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrasodium bromide (MTT; Chemicon International, Temecula,
CA, USA) dye absorbance. Cells were pulsed with 10 μl of 5 mg/ml MTT to
each well for the last 4 h of 48 h and/or 72 h cultures, followed by 100 μl
isopropanol containing 0.04 N HCl. Absorbance was measured at 570/630-
nm using a spectrophotometer (Molecular Devices Corp., Sunnyvale,
CA, USA).
Immunoblotting
Cells cultured with the reagents were harvested, washed and lysed using
RIPA (radioimmunoprecipitation assay) lysis buffer with 5mM EDTA, 5 mM
EGTA (ethylene glycol tetraacetic acid), 5 mM NaF, 1 mM Na3VO4, 1 mM
PMSF (phenylmethanesulfonylﬂuoride), and complete protease inhibitor
cocktail (Roche Diagnostics, Indianapolis, IN, USA). Whole-cell lysates were
subjected to SDS-polyacrylamide gel electrophoresis, transferred to
nitrocellulose membrane (Bio-Rad Laboratories, Hercules, CA, USA) and
immunoblotted with speciﬁc Abs.
Flow cytometric analysis
For annexin-V–PI staining, MM.1S cells cultured for 24 h with SAHA (0.5 μM)
and/or lenalidomide (2.5 μM) were washed with phosphate-buffered saline
and processed according to manufacturer’s protocol (FITC Annexin V
Apoptosis Detection Kit I; BD Pharmingen, San Diego, CA, USA).
Co-cultures with BMSC culture media
To evaluate the effect of Len, ACY1215 or the combination on MM cell
growth in the context of the BM microenvironment, MM.1S and H929 cells
were cultured with these agents, in the presence or absence of BMSC
culture supernatant (BMSC-CS). Cell growth was measured by MTT assay in
triplicate or quadruplicate.
siRNA transfection
For small interfering RNA (siRNA) transfection, scrambled, HDAC6 and
cereblon (CRBN) ‘ON-TARGETplus SMARTpool siRNA’ were purchased from
Thermo Scientiﬁc (Lafayette, CO, USA). siRNA transfection was carried out
by Amaxa electroporation system using ‘Cell Line Nucleofector Kit V’
solution, according to manufacturer's protocol (Lonza, Koln, Germany).
RNA extraction and reverse transcription PCR
RNA was extracted using Trizol (Invitrogen, Grand Island, NY, USA) and
quantiﬁed by a Nanodrop spectrophotometer (Labtech, East Sussex, UK).
Speciﬁcally, 5 × 106 cells were pelleted, washed with cold phosphate-
buffered saline and then resuspended in 1ml trizol. They were then
incubated with 1-bromo-3-chloropropane (Sigma), washed ﬁrst with
isopropyl alcohol and then with 75% ethanol, and resuspended in
nuclease-free water (Invitrogen). After quantiﬁcation, 2000 ng of RNA
was used to synthesize cDNA via the Superscript II First strand synthesis Kit
(Invitrogen), according to the manufacturer’s instructions. To evaluate the
expression levels of MYC, cereblon and GAPDH, quantitative real-time
reverse transcription PCR (qRT-PCR) was performed using SYBR GREEN PCR
Master Mix (Applied Biosystems, Life Technologies), after optimization of
the primer conditions. cDNAs were diluted 1:100 or 1:1000 and ampliﬁed in
a 20 μl reaction. Primers used (200 or 400 nM) are as follows: MYC, forward:
TTTTTCGGGTAGTGGAAA, reverse: GCAGTAGAAATACGGCTGCAC; CRBN,
forward: CAGTCTGCCGACATCACATAC, reverse: GCACCATACTGACTTCTTG
AGGG; GAPDH forward: GAAGGTGAAGGTCGGAGTCA, reverse: GGGGTCAT
TGATGGCAACAATA. Thermal cycling conditions were: 10 min at 95 °C,
40 cycles at 95 °C for 15 s; followed by 1min at 60 °C. qRT-PCR was
performed on ABI Prism 7300 Sequence Detection System (Applied
Biosystems). Data were analyzed using the delta Ct method, and GAPDH
was used as an invariant control.
Statistical analysis
Statistical signiﬁcance of differences observed in drug-treated versus
control cultures was determined using the Wilcoxon signed-ranks test. The
minimal level of signiﬁcance was Po0.05. The interaction between Len
and HDAC inhibitors was analyzed by isobologram analysis using the
CalcuSyn software program (Biosoft, Ferguson, MO, USA) to determine
whether the combination was additive or synergistic; a combination index
(CI)o1.0 indicates a synergistic effect.
RESULTS
IMiDs and HDAC inhibitors downregulate c-Myc expression
c-Myc has a crucial role in MM pathogenesis, and previous studies
have shown that IMiDs downregulate c-Myc expression in MM
cells.8 We therefore ﬁrst examined the inhibitory effect of Len and
Pom on c-Myc expression in our setting. Both agents markedly
downregulated c-Myc expression in MM.1S cells in a dose-
dependent manner. Pom has even more potent inhibitory activity
on c-Myc than Len (Figure 1a). HDAC inhibitors also have been
shown to downregulate c-Myc in other cell types,20,21 and we next
examined their inhibitory effect on c-Myc expression in MM. In
these experiments, we employed two class-I/II (LBH589, panobi-
nostat; SAHA, vorinostat) and a class-I selective (MS275, entinostat)
HDACi. Consistent with previous studies, LBH589 and SAHA
downregulated c-Myc expression in a dose-dependent manner
(Figure 1b). MS275 also signiﬁcantly downregulated c-Myc
expression associated with increased acetylation in histones, but
not acetylation of the class-IIb HDAC6 substrate α-tubulin
(Figure 1c). These results strongly suggest that downregulation
of c-Myc by HDAC inhibitors is due to class-I HDAC inhibition.
IMiDs in combination with HDAC inhibitors show synergistic
cytotoxicity
We next examined the combination effect of IMiDs and HDACi on
MM cytotoxicity. MTT assay showed that combination treatment
induced synergistic cytoxicity in MM.1S cells (Figure 2a,
Supplementary Figure S1). Annexin-V/PI staining conﬁrmed that
the combination triggered apoptosis. For example, the population
of annexin-V-positive cells after treatment with Len or SAHA was
7.8% and 14.4%, respectively, which increased to 37.9% after
combination treatment (Figure 2b). Immunoblotting was carried
out to examine the molecular mechanism of apoptosis. Combina-
tion treatment markedly downregulated c-Myc and XIAP without
affecting Bcl2 or cIAP1 anti-apoptotic proteins; as well as triggered
cleavage of caspase-8, -9 and -3 (Figure 2c), indicating that Len
with SAHA triggered apoptosis by activating caspases and
downregulating anti-apoptotic factors. Of note, downregulation
of c-Myc is due to inhibition of mRNA levels, evidenced by qRT-
PCR (Figure 2d).
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HDACi can downregulate cereblon and antagonize the effect
of IMiDs
Synergistic cytotoxicity was also observed after Len treatment in
combination with class-I HDACi MS275 (Figure 3a, Supplementary
Figure S2) or ACY1215, an HDAC6 inhibitor with minimal class-I
inhibitory effect, in MM.1S cells (Supplementary Figure S3); as well
as in H929 cells treated with ACY1215 with Pom (Supplementary
Figure S4). Since we have previously shown that sequential
treatment of doxorubicin followed by bortezomib triggers
signiﬁcant cytotoxicity,22 we similarly examined whether pretreat-
ment with MS275 enhances Len-induced cytotoxicity in MM.1S
cells. Unexpectedly, we observed an antagonistic effect of MS275
on Len-induced cytotoxicity (Figure 3b, Supplementary Figure
S5A). Importantly, this antagonistic effect against Len was not
observed after pretreatment with ACY1215 on the same schedule
(Figure 3c, Supplementary Figure S5B). Previous studies have
shown that IMiDs bind to CRBN, followed by degradation of
IKZF1/3;4,5 moreover, downregulation of CRBN confers resistance
to IMiDs treatment.2,3 We therefore next examined whether
various HDACi modulate expression and/or function of CRBN. Both
MS275 and ACY1215 downregulated c-Myc in a dose-dependent
manner; moreover, MS275 (41 μM), but not ACY1215, also
markedly suppressed CRBN expression (Figure 3d). Similar results
were observed in MM.1S and H929 cells treated with SAHA with
Len (Figure 3e). To examine whether downregulation of CRBN
abrogates cytotoxicity of combination treatment, we knocked
down CRBN using siRNA in H929 cells (Figure 3f, upper panel).
Consistent with previous studies, we conﬁrmed that CRBN
knockdown cells acquired resistance to the Len treatment
(Figure 3f, lower panel). Taken together, these results indicate
that potent inhibition of class-I HDACs is not required for
combination treatment with IMiDs to obtain synergistic cytotoxi-
city. Moreover, treatment with class-I/II or potent class-I HDACi
before IMiD treatment antagonizes IMiD-induced cytotoxicty due
to downregulation of CRBN.
Since HDACi downregulates c-Myc mRNA, we similarly exam-
ined mRNA level of CRBN after treatment with ACY1215 and
MS275. Unlike c-Myc, mRNA of CRBN was upregulated by the
treatment (Figure 3g), suggesting upregulation of mRNA due to a
positive feedback mechanism. Since proteases (that is, caspases)
cleave a number of proteins, we cultured MM cells with MS275 in
the presence or absence of pan-caspase inhibitor Z-VAD-FMK
(ZVAD). Although ZVAD inhibited MS275-induced cleavage of
PARP and cytotoxicity, it did not block downregulation of cereblon
(Figure 3h, Supplementary Figure S6), indicating a non-caspase-
dependent mechanism of CRBN downregulation.
ACY1215 downregulates IKZF1 and IKZF3
Since Len in combination with ACY1215-triggered synergistic
cytotoxicity in MM cells (Figure 3), we next asked whether
inhibition of HDAC6 mediated this effect. As in previous studies,15
we knocked down HDAC6 using targeted siRNA in H929 cells.
HDAC6 knockdown did not alter c-Myc expression (Figure 4a),
consistent with our experiments showing that c-Myc down-
regulation by HDAC inhibitors is due to class-I inhibitory effect
(Figure 1). Moreover, HDAC6 knockdown did not enhance Len-
induced cytotoxicity (Figure 4b), further indicating that this effect
is not due to inhibition of class-IIb HDAC. These results indicate
that HDAC6 does not modulate either c-Myc expression or
sensitivity to Len treatment.
Since ACY1215 with Len triggered signiﬁcant cytotoxicity
without downregulating CRBN expression, we next examined
the molecular mechanism mediating the synergistic effect of this
combination treatment. IKZF1 (Ikaros) and IKZF3 (AIolos) have
been shown to have crucial role in MM cell survival. Speciﬁcally,
IKZF1/3 are degraded via activation of CRBN upon IMiD treatment,
thereby triggering MM cell growth inhibition.4,5 We here observed
that ACY1215 markedly downregulated IKZF1, IRF4 and c-Myc in a
dose-dependent manner (Figure 4c). Importantly, low doses of
Len with ACY1215 signiﬁcantly reduced expression of c-Myc, IKZF1
and IKZF3 without affecting CRBN expression, suggesting that
downregulation of IKZF1/3 may contribute to the cytotoxicity
induced by this combination. Len with ACY1215 treatment is
similarly effective against primary MM cells from patients (n= 7;
Figure 4e).
Len with ACY1215 blocks BMSC-induced upregulation of c-Myc
The BM microenvironment has a crucial role in MM pathogenesis
by promoting tumor cell proliferation, survival and drug
resistance.23 Therefore we next examined whether the BM
microenvironment modulates c-Myc, IKZF1 or CRBN expression.
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Figure 1. IMiDs and HDACi downregulate c-Myc. (a) MM.1S cells were cultured with Len or Pom for 48 h. (b) MM.1 S cells were cultured with
LBH589 or SAHA for 48 h. (c) MM.1S cells were cultured with MS75 for 12 or 24 h. Whole-cell lysates were subjected to immunoblotting with
indicated Abs. The arrow indicates acetylated-α-tubulin as a biomarker of HDAC6 inhibition.
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BMSC-CS upregulated c-Myc, but not IRF4, expression in MM.1S
and H929 cells (Figure 5a). Of note, phospho-STAT3 served as
positive control for BMSC-SC-triggered signaling. Conversely, Len
markedly downregulated c-Myc expression in a dose-dependent
manner, even in the presence of BMSC-CS (Figure 5b). Importantly,
combination treatment with Len and ACY1215 signiﬁcantly
downregulated c-Myc and XIAP, associated with caspase-3
cleavage (Figure 5c). Moreover, this combination induced
synergistic MM cell growth inhibition even in the presence of
BMAC-SC (Figure 5d). These data indicate that combination
treatment can overcome BM microenvironment-mediated growth
and drug resistance.
ACY1215 enhances cytotoxicity induced by Len with
dexamethasone or Len with bortezomib
Since Len in combination with dexamethasone (Dex) is a standard
treatment for MM, we next asked whether ACY1215 enhances
cytotoxicity induced by this treatment. Indeed, ACY1215
enhanced MM cell growth inhibition by Len with Dex
(Figure 6a). Immunoblotting demonstrated that ACY1215 down-
regulated c-Myc, as well as upregulated cleavage of caspase-3 and
PARP, in a dose-dependent manner. Acetylated α-tubulin served
as positive control for HDAC6 inhibition (Figure 6b).
Len with BTZ is another standard treatment option for MM.
Moreover, we and others have show that HDAC inhibitors
enhance BTZ-induced cytotoxicity. Speciﬁcally, HDAC6 inhibitor
tubacin or ACY1215 with BTZ or carﬁlzomib show synergistic MM
cytotoxicity, associated with accumulation of polyubiquitinated
proteins and endoplasmic reticulum stress.15–17 Therefore, we also
examined whether ACY1215 enhances cytotoxicity triggered by
Len with BTZ. As shown in Figure 6c, ACY1215 in a dose-
dependent manner enhanced growth inhibition triggered by Len
with BTZ. Taken together, our results indicate that ACY1215 can be
utilized to enhance MM cytotoxicity induced by standard MM
treatment options that include Len and/or BTZ.
DISCUSSION
The proto-oncogene c-MYC encodes a transcription factor c-Myc,
an oncoprotein which in turn is closely regulated by many
mechanisms.24 In MM, MYC has a crucial role pathogenesis:
expression of MYC is increased in newly diagnosed MM compared
with monoclonal gammopathy of undetermined signiﬁcance,
suggesting that increased MYC expression is associated with
progression from monoclonal gammopathy of undetermined
signiﬁcance to MM.25,26 Moreover, c-Myc regulates its transcrip-
tional target genes involved in MM cell proliferation, apoptosis
and metabolism.27 Therefore, c-Myc is an attractive therapeutic
target for the treatment of MM.
Len is a clinically active therapy that downregulates c-Myc
expression in MM.8 In preclinical studies we have also reported
0
20
40
60
80
100
120
%
 c
on
tro
l
Casp-8
Casp-3
Casp-9
XIAP
-tub
Bcl2
cIAP1
c-Myc
C L S L+S 
Control Len (2.5µM) 
SAHA (0.5µM) SAHA+Len
0.7% 2.7% 
93.5% 3.1% 
1.1% 2.4% 
91.1% 5.4% 
0.8% 11.5%
77.6% 3.1%
1.0% 13.7%
61.1% 24.2%
0 1.25 2.5 5 
Lenalidomide (µM) 
Figure 2. Len in combination with SAHA triggers synergistic cytotoxicity. (a) MM.1S cells were cultured with Len (1.25–5 μM ) with vehicle
control (□), and with 0.25 (■), 0.5 (■) or 1 μM (■) SAHA for 48 h. Cell growth was assessed by MTT assay, and data represent mean± s.d. from
three independent experiments. CI was calculated by CalcuSyn software program. (b–d) MM.1S cells were cultured with Len (2.5 μM) in the
presence or absence of SAHA (0.5 μM) for 24 h. (b) Cells were harvested and subjected to annexin-V (X-axis)/PI (Y-axis) staining. Numbers
indicate cell population in each quadrant. (c) Whole-cell lysates were subjected to immunoblotting with indicated Abs. (d) Cells were
subjected to qRT-PCR analysis of c-Myc; 1, control; 2, Len 1.25 μM; 3, Len 2.5 μM; 4, Len 5 μM; 5, SAHA 0.25 μM; 6, SAHA 0.5 μM; 7, Len 2.5 μM+SAHA
0.25 μM; 8, Len 2.5 μM+SAHA 0.5 μM. Fold changes were normalized with internal control (GAPDH).
HDAC inhibitors and immunomodulatory drugs in myeloma
T Hideshima et al
4
Blood Cancer Journal
020
40
60
80
100
120
0
20
40
60
80
100
120
0 
20 
40 
60 
80 
100 
120 
0
20
40
60
80
100
120
%
 c
on
tro
l 
%
 c
on
tro
l 
0 0.3 1 3 
Lenalidomide (µM) 
%
 c
on
tro
l 
0 0.3 1 3 
Lenalidomide (µM) 
CRBN
c-Myc
GAPDH
C 2 1 4 0.5 2 1 0.5 0.25 
ACY1215 (µM) MS275 (µM) 
0 1 2 0 1 µM
CRBN
GAPDH
SAHA
MM.1S H929 
CRBN
GAPDH
siRNA
Sc
Sc
CRBN
CRBN 
0 0.3 1 
Lenalidomide
0
0.5
1
1.5
2
2.5
DMSO 1 3 1 3 
ACY1215 MS275 
Fo
ld
 c
ha
ng
e 
PARP
CRBN
GAPDH
C Z MS MS+Z 
0 0.3 1 3 
Lenalidomide (µM) 
Figure 3. Class-I/II HDACi downregulate CRBN. (a) MM.1 S cells were simultaneously treated with Len in the presence of 0 (□), 0.125 (■),
0.25 (■), 0.5 (■) or 1 μM (■) for 72 h. (b) MM.1S cells were treated with 0 (□), 0.031 (■), 0.062 (■) or 0.125 μM (■) MS275 for 48 h. Cells were
then further treated with Len (0.1, 0.3 and 1 μM) for 48 h. (c) MM.1S cells were treated with 0 (□), 0.125 (■), 0.25 (■), 0.5 (■), 1 (■) and 2 μM (■)
ACY1215 for 48 h. Cells were then further treated with Len (0.1, 0.3 and 1 μM) for 48 h. Cell growth was assessed by MTT assay. The data
represent mean± s.d. from three independent experiments. CI was calculated by CalcuSyn software program. (d) MM.1S cells were cultured
with increasing doses of ACY1215 or MS275 for 48 h. (e) MM.1S cells and H929 cells were treated with SAHA for 48 h. Whole-cell lysates were
subjected to immunoblotting with indicated Abs. (f) H929 cells were transfected with scrambled (Sc) or CRBN-targeted siRNA. Whole-cell
lysates were subjected to immunoblotting with indicated Abs (upper panel). Transfected cells were also cultured with Len (0.3 and 1 μM) for
72 h. Cell growth was assed by MTT assay. (g) MM.1S cells were treated with ACY1215 or MS275 (1 and 3 μM) for 48 h. mRNAs were subjected to
qRT-PCR for CRBN. Fold changes were normalized with GAPDH. (h) MM.1S cells were cultured with MS275 (1 μM) in the absence or presence of
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that JQ1, a small molecule inhibitor of bromodomain (BRD) 4, can
inhibit MYC RNA expression and MM cell growth.28 Moreover,
synergistic anti-tumor activity of Len with another BRD inhibitor
CPI203 has been reported in BTZ-resistant mantle cell
lymphoma.29 Class-I/II HDACi SAHA and valproic acid also inhibit
c-Myc expression in Ph1-positive acute leukemia21 and acute
myeloid leukemia cells,30 respectively. Here we showed that IMiDs
with HDACi trigger signiﬁcant downregulation of c-Myc in MM,
associated with synergistic cytotoxicity.
Several classes of HDACi targetting different isoforms9 are
under clinical evaluation in MM. In this study, we ﬁrst tested
hydroxamic acid class HDACi SAHA and LBH589, as well as a
benzamide class HDACi MS275. Consistent with previous
studies,21,30 each of these HDACi signiﬁcantly downregulate
c-Myc expression in MM cells. Importantly, SAHA and LBH589
inhibit both class-I and -II HDACs, whereas MS275 inhibits only
class-I HDACs, suggesting that downregulation of c-Myc by these
agents is due to inhibition of class-I HDACs (HDAC1, 2, 3 and 8).
We further showed that these HDACi with Len show synergistic
cytotoxicity associated with induction of caspase-8 and caspase-9
cleavage, activating both intrinsic and extrinsic apoptotic path-
ways. Previous studies have shown that XIAP has an important
role in MM cell survival by inhibiting apoptosis.31 Interestingly, in
our studies XIAP expression is markedly downregulated by Len
with HDACi, indicating that combination treatment not only
enhances MM cytotoxicity by activating apoptotic signaling, but
also inhibits anti-apoptotic protein expression.
Recent studies have shown that CRBN is a direct binding protein
of IMiDs1,3 and act as an E3 ligase of IKZF1 and IKZF3. More
speciﬁcally, IMiDs bind to cereblon and promote proteasomal
degradation of IKZF1 and IKZF3 to trigger MM cell growth
inhibition.4,5 Previous studies show that knockdown of CRBN
confers resistance to IMiDs treatment.2,3 In this study, we
conﬁrmed that CRBN knockdown H929 cells are less sensitive to
IMiD treatment than parental cells. Importantly, we found
that class-I/II HDACi (SAHA) and class-I-selective HDACi
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(MS275)-downregulated CRBN in a caspase-independent manner.
Consistent with this result, sequential treatment with MS275
followed by Len was antagonistic, whereas simultaneous treat-
ment triggers synergistic cytotoxicity. Previous studies in a murine
xenograft model have shown efﬁcacy of combination treatment of
Len with LBH589, and that mice receiving combination treatment
had longer survival than those treated with either Len or LBH589
alone.32 Importantly, our results suggest that potent class-I/II or
class-I-selective HDACi reduce MM cell sensitivity to IMiDs due to
downregulation of CRBN. Therefore HDACi belonging to different
classes and/or targeting different HDAC isoforms, as well as
modiﬁcation of treatment schedule, may be useful to maximize
anti-MM activities of Len-HDACi combination therapies.
ACY1215 is the ﬁrst-in-class clinically relevant HDAC6i with
minimal blockade of class-I HDACs. ACY1215 in combination with
proteasome inhibitors shows synergistic cytotoxicity in MM
cells,16,17 and combination treatment of ACY1215 with Len or
BTZ is under clinical evaluation.33 Interestingly and in contrast to
MS275 with Len combination, we did not observe downregulation
of CRBN when ACY1215 was added to Len. In addition, HDAC6
knockdown was not able to promote enhanced cytotoxicity
induced by Len. These data suggest that modest class-I inhibitory
activity of ACY1215, rather than its class-IIb HDAC inhibitory
activity, is mediating the enhanced cytotoxicity of this combina-
tion therapy. Taken together, these results have important clinical
implications and suggest that only modest inhibition of class-I
HDACs is required to induce synergistic cytotoxicity with Len, and
that more potent inhibition of class-I HDACs triggers down-
regulation of CRBN, thereby compromising the efﬁcacy of
combination therapy.
Having shown synergistic MM cytotoxicity triggered by Len and
ACY1215 without altering CRBN expression, we further examined
mechanisms mediating cytotoxicity of this combination treatment.
IKZF1 and IKZF3 are major targets of IMiDs downstream of
cereblon, associated with MM cell growth inhibition. Recently,
4200 CRBN binding proteins were identiﬁed which changed their
expression after Len treatment.34 We here recognized that
ACY1215 monotherapy downregulated IKZF1 only at relatively
high doses; however, it markedly inhibited both IKZF1 and IKZF3
at low doses when combined with Len. Moreover, in this study all
eight IKZF1 isoforms35 were downregulated by the combination of
ACY1215 Len treatment, without affecting CRBN expression.
Ongoing studies are further delineating molecular mechanisms
of this combination effect.
The BM microenvironment has a crucial role in proliferation,
survival and drug resistance of MM cells.23 Speciﬁcally, cell
proliferation and drug resistance are mediated by soluble factors
including interleukin-6, insulin-like growth factor 1 and vascular
endothelial growth factor. We therefore determined whether
combination treatment of Len with ACY1215 overcomes survival/
anti-apoptotic signaling triggered by these factors. To avoid
contamination of BMSCs in immunoblotting experiments, we
cultured MM cells with conditioned medium harvested from
BMSCs, which has been well validated in our previous studies.36,37
We observed marked upregulation of c-Myc induced by BMSC-CS.
Importantly, our results therefore suggest that the BM micro-
environment upregulates c-Myc, thereby promoting MM cell
proliferation and survival; conversely, Len with ACY1215 combina-
tion treatment can downregulate c-Myc and mediate MM
cytotoxicity even in the BM milieu.
Three-drug combination regimens incorporating corticosteroids
are common treatment options in MM. For example, RVD
(Revlimid+Velcade+Dexamethasone) is a one of the most effective
combination treatment strategies for relapsed/refractory MM38
and newly diagnosed MM,39 as well as for maintenance therapy in
MM.40 We therefore further examined combination treatment of
Len plus ACY1215 with or without Dex, and observed that Dex
further enhanced cytotoxicity and apoptosis. We and others have
shown that HDAC6 inhibition synergistically enhances cytotoxicity
of BTZ15,16 or carﬁlzomib17 in MM and non-Hodgkin lymphoma
cells41 by blocking protein degradation via both the aggresomal
and protesomal pathways. As expected, BTZ signiﬁcantly aug-
mented cytotoxicity induced by Len-Dex-ACY1215 combination
treatment. Taken together, our results show that ACY1215 may
enhance anti-MM activities of Len/Dex in combination BTZ due to
its inhibitory activities against class-I and class-IIb HDAC,
respectively, providing the preclinical rationale for RVD ACY1215
clinical trials to further improve patient outcome.
In conclusion, our results demonstrate that IMiDs with HDACi
induce synergistic cytotoxicity in MM, associated with down-
regulation of c-Myc. Importantly, choice of HDACi and treatment
schedules should be optimized to enhance cytotoxicity without
downregulating CRBN expression. In particular potent broad class-
I/II HDACi can downregulate CRBN and antagonize Len; in contrast
more selective HDACi with modest class-I HDAC inhibitory activity
of ACY1215 does not downregulate CRBN, thereby allowing for
synergistic MM cytotoxicity.
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